RecruitingNCT07587229

A Multicenter Observational Study to Develop and Validate an Alternative Splicing-Based Machine Learning Model for Predicting Response to 5-FU-Based Adjuvant Chemotherapy in Gastric Cancer (VERSA-GC Study)

Sponsor: City of Hope Medical Center

Trial Details

Condition	Gastric Cancer
Intervention	Observational study (no intervention)
Status	Recruiting
Participants	329
Est. Completion	1 Jan 2027
Last Updated	14 May 2026

Primary Outcome

Treatment response based on 3-year recurrence-free survival

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Pathologically confirmed stage II or III gastric cancer * Underwent curative surgical resection * Received 5-FU-based adjuvant chemotherapy * Availability of tumor tissue samples for analysis Exclusion Criteria: * History of other malignancies * Inadequate or poor-quality tissue samples (e.g., contamination)

Trial Sites

Countries

United States

View Registry Entry

Related Analysis

VERSA-GC Study: Machine Learning Model to Predict 5-FU Chemotherapy Response in Gastric Cancer — Precision Oncology Advances

The VERSA-GC study develops machine learning models using RNA splicing patterns to predict 5-FU chemotherapy response in gastric cancer. This precision oncology approach could revolutionise treatment selection for stage II-III patients.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service